Longitudinal Analysis of Oral Communication in Friedreich's Ataxia (ORFA)

• ClinicalTrials.gov Identifier: NCT04631224
• Recruitment Status: Completed
• First Posted: November 17, 2020
• Last Update Posted: November 19, 2020
• Sponsor: Institut National de la Santé Et de la Recherche Médicale, France
• Information provided by (Responsible Party): Institut National de la Santé Et de la Recherche Médicale, France

Study Description

Brief Summary:

Friedreich Ataxia (FA) is a hereditary neurological disease that is associated with a cerebellar syndrome and pyramidal symptoms. Clinical expression varies from one individual to another and throughout the evolution of the disease and is partially related to an abnormal expansion of the GAA triplet repeat in the frataxin gene. Dysarthria, a disorder in the motor production of speech, is always present in the clinical presentation of the disease (Schöls et al. 1997 ; Harding 1981 ; Dürr et al. 1996 ; Delatycki et al. 1999). It has been the subject of specific studies exploring the link between the evolution of dysarthria and disease progression (J. Folker et al. 2010; J. E. Folker et al. 2012; Rosen et al. 2012; Brendel et al. 2013). These studies allowed for the identification of markers for speech disintegration, specific to FA dysarthria, using perceptive voice measures, but also acoustics and objectives for qualifying voice and speech at the same time. The challenge is in finding measures sufficiently appropriate and sensitive to detect the evolution of these indicators throughout the course of the disease (Rosen et al. 2012). The neurological scales that take in to account all signs of a cerebellar syndrome are not sufficiently sensitive (Marelli et al. 2012). In addition, hearing difficulties develop during the course of the disease in addition to visual disturbances (gaze instability) which hinder communication. The ORFA study aims to evaluate oral communication in FA patients and identify appropriate measures that allow for the comparison of dysarthria pre and post-treatment in a clinical trial and can be used for the evaluation of efficacy.

Condition or disease
Friedreich Ataxia

Detailed Description:

The ORFA research study will depend partly on the EFACTS consortium (European Friedreich's Ataxia Consortium for Translational Studies) in which the French center ICM participates since 2011 (principal investigator Pr Alexandra Durr). The clinical registry EFACTS has included 604 FA patients to date who are followed annually with the goal of collecting clinical and biological information via a database. In Paris, 50 FA patients are followed and receive a complete evaluation at each visit: clinical evaluations, blood test, cardiac evaluation, and neuropsychological evaluation. In addition, ORFA will be closely linked with the CERMOI project, entitled "Integrated functional evaluation of the cerebellum" which will study visual motor disturbances in FA. This project received funding in 2014 through the IHU-A-ICM, Institute of translational and neuroscientific research which includes 4 research teams at the ICM. CERMOI will combine clinical examination, recording of ocular movements, vestibular testing, gait and posture tests.

ORFA will enable to assess the difficulties in articulation and hearing in FA patients and correlate this data with clinical and biological data collected in EFACTS. 50 francophone FA patients will be followed for 2 visits with a one-year interval in between.

Study Design

• Study Type: Observational
• Actual Enrollment: 40 participants
• Observational Model: Cohort
• Time Perspective: Prospective
• Official Title: Longitudinal Analysis of Oral Communication in Friedreich's Ataxia
• Actual Study Start Date: February 2015
• Actual Primary Completion Date: December 2016
• Actual Study Completion Date: February 2017

Groups and Cohorts

Outcome Measures

Primary Outcome Measures :

1. To identify a sensitive marker of disease progression in Friedreich's Ataxia patients by assessing the speech, voice, oromotor function, and hearing. [ Time Frame: Longitudinal timeframe with a first evaluation at baseline and second evaluation one year later ]

   - Speech therapy assessment: We conduct a statistical study to cross-reference independent variables (age, sex…) and dependent variables. This is to identify relevant and sensitive metrics to capture changes over one year. Dysarthria is assessed by the compensations implemented by patients to maintain the intelligibility of their speech. For example, patients can compensate for their difficulty by slowing the speech flow to maintain good intelligibility. Speech therapy is based on the understanding of these compensation phenomena and uses them in rehabilitation.

   - Recording of the hearing: This non-invasive examination will include tonal audiometry: detection of perception thresholds for sounds of different frequencies and voice audiometry to assess comprehension and intelligibility. This assessment may be supplemented by studying nerve conduction along the auditory pathways. These examinations help to identify the modalities of hearing rehabilitation.

Eligibility Criteria

• Ages Eligible for Study: 18 Years to 65 Years (Adult, Older Adult)
• Sexes Eligible for Study: All
• Sampling Method: Non-Probability Sample

Study Population

Inclusion Criteria:

• To have Friedreich's Ataxia.
• To be francophone
• Being a reader
• Agreeing to be part of a research protocol and longitudinal follow-up
• Agree to provide access to medical records

Exclusion Criteria:

• Non-French speaking
• Psychiatric disorders

Criteria

Inclusion Criteria:

• To have Friedreich's Ataxia.
• To be francophone
• Being a reader
• Agreeing to be part of a research protocol and longitudinal follow-up
• Agree to provide access to medical records

Exclusion Criteria:

• Non-French speaking
• Psychiatric disorders

Contacts and Locations

No Contacts or Locations Provided

More Information

• Responsible Party: Institut National de la Santé Et de la Recherche Médicale, France
• ClinicalTrials.gov Identifier: NCT04631224
• Other Study ID Numbers: 2011-000389-32
• First Posted: November 17, 2020
• Last Update Posted: November 19, 2020
• Last Verified: August 2015

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:

Ataxia; Cerebellar Ataxia; Friedreich Ataxia; Dyskinesias; Neurologic Manifestations; Nervous System Diseases; Cerebellar Diseases; Brain Diseases; Central Nervous System Diseases; Spinocerebellar Degenerations; Spinal Cord Diseases; Heredodegenerative Disorders, Nervous System; Neurodegenerative Diseases; Genetic Diseases, Inborn; Mitochondrial Diseases; Metabolic Diseases